Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.5%

2 terminated/withdrawn out of 19 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

25%

3 of 12 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
5(55.6%)
Phase 4
3(33.3%)
Phase 1
1(11.1%)
9Total
Phase 2(5)
Phase 4(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT07403825Phase 4Not Yet Recruiting

Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material

Role: collaborator

NCT06991946Recruiting

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

Role: collaborator

NCT04602078Phase 2Completed

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Role: collaborator

NCT04793399Phase 1Terminated

Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Role: collaborator

NCT01377363Completed

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

Role: collaborator

NCT03829306Completed

Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)

Role: collaborator

NCT04186013Phase 2Active Not Recruiting

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Role: collaborator

NCT03801304Phase 2Completed

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer

Role: collaborator

NCT03732859Completed

PROOF-Registry New and Extended Belgium -Luxembourg

Role: collaborator

NCT02583516Phase 2Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Role: collaborator

NCT01733628Completed

Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer

Role: collaborator

NCT01598285Terminated

A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer

Role: collaborator

NCT03083756Completed

Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients

Role: collaborator

NCT02076971Completed

Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive

Role: collaborator

NCT02087696Phase 4Unknown

Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis

Role: collaborator

NCT01913873Phase 4Completed

High-sensitivity Troponin in Cardiac Surgery

Role: collaborator

NCT01338753Phase 2Completed

Study to Evaluate Markers of Response in Locally Advanced Breast Cancer

Role: collaborator

NCT01473849Unknown

Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients

Role: collaborator

NCT01433926Completed

Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years

Role: collaborator

All 19 trials loaded